WHAT IS CLAIMED IS:

1. An isolated nucleic acid molecule comprising:

a polynucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:3, SEQ ID NO:5 or a polynucleotide sequence which hybridizes under stringent conditions with at least one of the foregoing sequences; and

a nucleotide sequence encoding at least one putative N-glycosylation site inserted therein.

- 2. An isolated polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO:2, SEQ ID NO:4 and SEQ ID NO:6 and having at least one putative N-glycosylation site inserted therein.
- 3. The isolated nucleic acid molecule of claim 1, wherein the at least one putative N-glycosylation site consists of a nucleotide sequence that encodes an amino acid sequence of NXT.
- 4. The isolated nucleic acid molecule of claim 1, wherein the at least one putative N-glycosylation site is inserted at nucleotides 286-294 of SEQ ID NO:1, SEQ ID NO:3 or SEQ ID NO:5.
- 5. An isolated polypeptide produced by expression of the nucleic acid molecule of claim 1.
- 6. An isolated polypeptide of claim 2 which binds a Vascular Endothelial Growth Factor Receptor-1.
- 7. A vector comprising a nucleic acid molecule of claim 1.

- 8. A host cell transformed or transfected with a vector according to claim 7.
- 9. A pharmaceutical composition comprising an effective amount of a polypeptide of claim 2.
- 10. The pharmaceutical composition of claim 9, further comprising heparin.
- 11. A method of making a soluble VEGF-B $_{167}$ from a host cell, comprising:

inserting at least one putative N-glycosylation site into a nucleotide sequence of SEQ ID NO:1;

transforming or transfecting said nucleotide sequence with inserted N-glycosylation site into a host cell;

culturing the transfected host cell in a growth medium such that said nucleotide sequence with inserted N-glycosylation site is expressed; and

isolating the expressed polypeptide from the growth medium in which said host cell was cultured.

- 12. The method of claim 11, further comprising exposing the cultured transfected host cell to heparin after said polypeptide is expressed.
- 13. The method of claim 11, wherein the at least one putative N-glycosylation site consists of a nucleotide sequence that encodes an amino acid sequence of NXT.
- 14. The method of claim 11, wherein the nucleotide sequence encoding the at least one putative N-glycosylation site is inserted at nucleotides 286-294 of SEQ ID NO:1.

15. A method of increasing an amount of a soluble VEGF- B_{167} , VEGF- B_{186} or VEGF- B_{Ex1-5} polypeptide from a host cell, comprising:

inserting at least one putative N-glycosylation site into a nucleotide sequence selected from the group of nucleotides sequences of SEQ ID NO:1, SEQ ID NO:3 or SEQ ID NO:5;

transforming or transfecting said nucleotide sequence with inserted N-glycosylation site into a host cell;

culturing the transfected host cell in a growth medium such that said nucleotide sequence with inserted N-glycosylation site is expressed; and

isolating the expressed polypeptide from the growth medium in which said host cell was cultured.

- 16. The method of claim 15, further comprising exposing the cultured transfected host cell to heparin after said polypeptide is expressed.
- 17. The method of claim 15, wherein the at least one putative N-glycosylation site consists of a nucleotide sequence that encodes an amino acid sequence of NXT.
- 18. The method of claim 15, wherein the nucleotide sequence encoding the at least one putative N-glycosylation site is inserted at nucleotides 286-294 of SEQ ID NO:1, SEQ ID NO:3 or SEQ ID NO:5.